Medicare Enrolled

Dr. Mary Ann Skiba, D.O.

Hematology · Fort Worth, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
800 W MAGNOLIA AVE, Fort Worth, TX 76104
8177597000
In practice since 2006 (19 years)
NPI: 1093765596 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Skiba from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Skiba? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Skiba

Dr. Mary Ann Skiba is a hematology in Fort Worth, TX, with 19 years in practice. Based on federal Medicare data, Dr. Skiba performed 61,914 Medicare services across 586 unique beneficiaries.

Between the years covered by Open Payments, Dr. Skiba received a total of $41,361 from 46 pharmaceutical and/or device companies across 222 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Skiba is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 6% volume in TX$ $41,361 industry payments

Medicare Practice Summary

Medicare Utilization ↗
61,914
Medicare services
Top 6% in TX for hematology
586
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,259 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron infusion (Injectafer)40,500$1$3
Iron infusion (Feraheme)10,710$0$3
Epoetin alfa injection (Procrit) for anemia9,260$6$28
Drug injection, under skin or into muscle365$10$60
COVID-19 test, self-administered204$12$30
Office visit, established patient (30-39 min)177$84$275
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less149$47$190
Office visit, established patient (20-29 min)148$64$175
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg106$1$5
Office visit, established patient, complex (40-54 min)76$125$350
Hospital follow-up visit, moderate complexity54$62$175
New patient office visit (45-59 min)48$112$400
Telephone medical discussion with physician, 5-10 minutes31$29$100
Hospital follow-up visit, high complexity27$89$250
Initial hospital admission, high complexity19$135$500
Drawing of blood for a medical problem18$71$280
Nuclear medicine study from skull base to mid-thigh with ct scan11$1,084$4,069
New patient office visit, complex (60-74 min)11$158$500
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
83.0% high complexity
15.7% medium
1.3% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$41,361
Total received (2018-2024)
Avg $5,909/year across 7 years
Top 18% in TX for hematology
46
Companies
222
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$26,611 (64.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$10,103 (24.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,647 (11.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,234
2023
$5,148
2022
$1,064
2021
$484
2020
$3,328
2019
$10,483
2018
$17,620

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$19,488
E.R. Squibb & Sons, L.L.C.
$5,746
AstraZeneca Pharmaceuticals LP
$4,250
Pharmacosmos Therapeutics Inc.
$2,999
Alexion Pharmaceuticals, Inc.
$2,891
Celgene Corporation
$2,669
GlaxoSmithKline, LLC.
$351
Astellas Pharma US Inc
$179
Takeda Pharmaceuticals U.S.A., Inc.
$173
Incyte Corporation
$163
Exelixis Inc.
$157
Janssen Biotech, Inc.
$143
PUMA BIOTECHNOLOGY, INC.
$136
Verastem, Inc.
$132
ADC Therapeutics America, Inc.
$128
Daiichi Sankyo Inc.
$127
Puma Biotechnology, Inc.
$125
Merck Sharp & Dohme Corporation
$121
Ipsen Biopharmaceuticals, Inc
$117
AbbVie, Inc.
$110
Lilly USA, LLC
$104
BeiGene USA, Inc.
$98
Teva Pharmaceuticals USA, Inc.
$93
Pharmacyclics LLC, An AbbVie Company
$91
Amgen Inc.
$85
Apellis Pharmaceuticals, Inc.
$84
GENZYME CORPORATION
$72
PharmaEssentia USA Corporation
$69
Novartis Pharmaceuticals Corporation
$67
Tempus AI, Inc
$51
ABBVIE INC.
$44
TAIHO ONCOLOGY, INC.
$41
Bayer HealthCare Pharmaceuticals Inc.
$29
Seattle Genetics, Inc.
$28
SOBI, INC
$28
AbbVie Inc.
$27
Regeneron Healthcare Solutions, Inc.
$21
Genentech USA, Inc.
$17
Seagen Inc.
$15
MorphoSys, US Inc.
$14
Epizyme, Inc.,
$14
Genmab U.S., Inc.
$13
Dova Pharmaceuticals
$13
SANOFI-AVENTIS U.S. LLC
$12
Boehringer Ingelheim Pharmaceuticals, Inc.
$12
TOLMAR Pharmaceuticals, Inc.
$11
Top 3 companies account for 71.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · ADVATE · Abraxane · Aliqopa · BESREMI · BLENREP · BOSULIF · BRUKINSA · CABLIVI · CALQUENCE · CHANTIX · Cabometyx · Copiktra · DARZALEX · DAURISMO · Doptelet · ELIGARD · ELIQUIS · EMPLICITI · ENHERTU · ERBITUX · Empaveli · Enhertu · Epkinly · GAZYVA · GILOTRIF · GRANIX · IMBRUVICA · IMFINZI · INJECTAFER · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · Kyprolis · LIBTAYO · LONSURF · LUTATHERA · Luspatercept · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OJJAARA · OPDIVO · Onivyde · PROMACTA · REBLOZYL · Revlimid · SOLIRIS · SUTENT · TAGRISSO · TAZVERIK · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VONVENDI · Vanflyta · Venclexta · XOSPATA · XTANDI · Xofigo · Xtandi
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (64%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology and does not inherently indicate bias, but patients may wish to be aware.

Equivalent to $67 per 100 Medicare services performed
Looking for a hematology in Fort Worth?
Compare hematologys in the Fort Worth area by procedure volume, costs, and industry payment transparency.
Browse hematologys nearby

Geographic Context

Hematologys within 10 mi
1
Per 100K population
0.0
County median income
$81,905
Nearest hospital
JPS HEALTH NETWORK
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Skiba is a mixed practice specialist, with above-average Medicare volume (top 6% in TX), and high industry engagement (speaking/promotional, top 18%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Skiba experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Skiba performed 40,500 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Skiba receive payments from pharmaceutical companies?
Yes. Dr. Skiba received a total of $41,361 from 46 companies across 222 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Skiba's costs compare to other hematologys in Fort Worth?
Dr. Skiba's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Skiba) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →